[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-565775-105":3,"detail-sidebar-cat-1-en-105":81,"doc-detail-565775-en":127},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","numelvi-atinvicitinib-tablets-immunomodulator","NUMELVI - atinvicitinib tablets - Immunomodulator","","NUMELVI (atinvicitinib tablets) is an oral immunomodulator for dogs, containing a synthetic selective JAK1 inhibitor. It is indicated for controlling pruritus associated with allergic dermatitis in dogs 6 months and older. The recommended once-daily dosing is 0.36 to 0.54 mg atinvicitinib/lb (0.8 to 1.2 mg/kg) with food, using the provided dosing table by body weight. Safety information includes use restrictions, infection monitoring, and adverse reaction data through day 28 in a 144 vs 144 study.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/template/","Template",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/template/general/","General",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/template/numelvi-atinvicitinib-tablets-immunomodulator/565775/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/numelvi-atinvicitinib-tablets-immunomodulator/565775.png","ImageObject",442,249,{"name":42,"@type":43},"hdkawk","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-10-13",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is NUMELVI and what is its active ingredient?","Question",{"text":63,"@type":64},"NUMELVI is an immunomodulator. Its active ingredient is atinvicitinib, a synthetic selective JAK1 inhibitor.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"For which dogs and condition is NUMELVI indicated?",{"text":68,"@type":64},"NUMELVI is indicated for controlling pruritus associated with allergic dermatitis in dogs 6 months of age and older.",{"name":70,"@type":61,"acceptedAnswer":71},"How should NUMELVI be administered and at what dose?",{"text":72,"@type":64},"Administer NUMELVI orally once daily with food. The dose is 0.36 to 0.54 mg atinvicitinib per lb (0.8 to 1.2 mg atinvicitinib/kg) based on the provided dosing table.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},565775,1792086777,{"code":4,"msg":82,"data":83},"success",[84,89,94,99,104,109,114,119,124],{"id":85,"doc_module":22,"doc_module_name":25,"category_name":86,"show_sort_weight":87,"slug":88},11,"Presentations",90,"presentations",{"id":90,"doc_module":22,"doc_module_name":25,"category_name":91,"show_sort_weight":92,"slug":93},12,"Resumes",80,"resumes",{"id":95,"doc_module":22,"doc_module_name":25,"category_name":96,"show_sort_weight":97,"slug":98},14,"Invoices",70,"invoices",{"id":100,"doc_module":22,"doc_module_name":25,"category_name":101,"show_sort_weight":102,"slug":103},15,"Posters",60,"posters",{"id":105,"doc_module":22,"doc_module_name":25,"category_name":106,"show_sort_weight":107,"slug":108},16,"Social Media",50,"social-media",{"id":110,"doc_module":22,"doc_module_name":25,"category_name":111,"show_sort_weight":112,"slug":113},17,"Forms",40,"forms",{"id":115,"doc_module":22,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},18,"Letters",30,"letters",{"id":120,"doc_module":22,"doc_module_name":25,"category_name":121,"show_sort_weight":122,"slug":123},21,"Paper Templates",5,"papers-templates",{"id":125,"doc_module":22,"doc_module_name":25,"category_name":29,"show_sort_weight":4,"slug":126},158,"general-158",{"code":4,"msg":82,"data":128},{"doc_id":79,"user_id":129,"nickname":42,"user_avatar":130,"doc_module":22,"category_id":125,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":131,"file_id":132,"file_url":133,"file_type":134,"file_size":135,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":95,"language":136,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":137,"faqs":138,"seo_title":139,"seo_description":12,"update_tm":140,"read_time":122},3985747859855,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","NUMELVI-atinvicitinib tablet  \nMerck Sharp & Dohme Corp.  \n----------  \nNumelvi™  \n(atinvicitinib tablets)  \nImmunomodulator 253661 R1  \nFor oral use in dogs only  \nCAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.  \nDESCRIPTION:  \nThe active ingredient in NUMELVI is atinvicitinib. Atinvicitinib is a synthetic selective Janus kinase (JAK) 1 inhibitor . The chemical (IUPAC) name of atinvicitinib is 1-[(3R,4S)-4-cyanooxan-3-yl]-3-[(2-fluoro-6-methoxypyridin-4-yl)amino]-1H-pyrazole-4-carboxamide.  \nINDICATIONS:  \nNUMELVI is indicated for the control of pruritus associated with allergic dermatitis in dogs 6 months of age and older .  \nDOSAGE AND ADMINISTRATION:  \nNUMELVI should be administered orally, once daily, at a dose of 0.36 to 0.54 mgatinvicitinib/lb (0 .8 to 1.2 mg atinvicitinib/kg) body weight according to the Dosing Table below.  \nNUMELVI should be administered with food.  \nDosing Table  \n\n| Body\u003Cbr>Weight\u003Cbr>Ranges\u003Cbr>(lb) | Body\u003Cbr>Weight\u003Cbr>Ranges\u003Cbr>(kg) | Number of Tablets to be Administered |  |  |  |\n| --- | --- | --- | --- | --- | --- |\n|  |  | 4 .8 mg\u003Cbr>tablets | 7 .2 mg\u003Cbr>tablets | 21 .6 mg\u003Cbr>tablets | 31 .6 mg\u003Cbr>tablets |\n| 4.4-6.5 | 2-2.9 | 0.5 |  |  |  |\n| 6.6-9.5 | 3-4.3 |  | 0.5 |  |  |\n| 9.6-13.3 | 4.4-6 | 1 |  |  |  |\n| 13.4-19.9 | 6.1-9 |  | 1 |  |  |\n| 20-29.8 | 9.1-13.5 |  |  | 0.5 |  |\n| 29.9-42.6 | 13.6-19.3 |  |  |  | 0.5 |\n| 42.7-58.4 | 19.4-26.5 |  |  | 1 |  |\n| 58.5-87 | 26.6-39.5 |  |  |  | 1 |\n| 87.1-118.9 | 39.6-54 |  |  |  | 1.5 |\n| 119-174.2 | 54.1-79 |  |  |  | 2 |\n| ≥ 174.3 | ≥79 .1 | Administer the appropriate combination of tablet\u003Cbr>strengths |  |  |  |\n\nWARNINGS:  \nUser Safety Warnings:  \nThis product is not for human use. Keep this and all drugs out of reach of children. Wash hands thoroughly with soap and water immediately after handling tablets . In case of accidental ingestion, seek medical attention immediately.  \nAnimal Safety Warnings:  \nDogs should be monitored for the development of infections because NUMELVI may increase susceptibility to opportunistic infections , including demodicosis and interdigital furunculosis (see Target Animal Safety) .  \nNUMELVI is not for use in dogs with serious infections .  \nNUMELVI is a JAK inhibitor . New neoplastic conditions (benign and malignant) have been reported in dogs treated with other JAK inhibitors .  \nConsider the risks and benefits of treatment prior to initiating NUMELVI in dogs with a history of recurrent demodicosis .  \nNUMELVI modulates the immune system.  \nNUMELVI is not for use in dogs less than 6 months of age (see Target Animal Safety) .  \nKeep NUMELVI in a secure location out of reach of dogs , cats , and other animals to prevent accidental ingestion or overdose.  \nPRECAUTIONS:  \nThe effectiveness and safety of NUMELVI have not been evaluated in a field study beyond 28 days (see Adverse Reactions and Effectiveness) .  \nThe safe use of NUMELVI has not been evaluated in breeding, pregnant, or lactating dogs . Decreased mean testes weight was observed in a laboratory safety study (see Target Animal Safety) .  \nThe safe use of NUMELVI has not been evaluated in combination with glucocorticoids , cyclosporine, or other systemic immunosuppressive agents .  \nADVERSE REACTIONS:  \nIn a masked field study assessing effectiveness and safety of NUMELVI for the control of pruritus associated with allergic dermatitis in dogs , 144 NUMELVI-treated dogs and 144 placebo-treated dogs were evaluated for safety for up to 28 days . Adverse reactions seen during the field study are summarized in Table 1 below.  \nTable 1 . Adverse Reactions through Day 28  \n\n| Adverse Reaction | NUMELVI (N= 144) Number of dogs (%) | Placebo (N= 144) Number of dogs (%) |\n| --- | --- | --- |\n| Vomiting or nausea | 10 (6 .9%) | 6 (4 . 2%) |\n\n\n| Otitis externa | 9 (6 . 3%) | 8 (5 . 6%) |\n| --- | --- | --- |\n| Hematuria (without urinary tract infection) | 7 (4 .9%) | 6 (4 . 2%) |\n| Anorexia | 6 (4 . 2%) | 5 (3 . 5%) |\n","cbCainXGY9aIXPaT","https://ap.wps.com/l/cbCainXGY9aIXPaT","pdf",1080531,"English","# DESCRIPTION\n## INDICATIONS\n## DOSAGE AND ADMINISTRATION\n## WARNINGS\n## PRECAUTIONS\n## ADVERSE REACTIONS\n## CONTACT INFORMATION\n## CLINICAL PHARMACOLOGY\n### Mechanism of Action","[{\"question\":\"What is NUMELVI and what is its active ingredient?\",\"answer\":\"NUMELVI is an immunomodulator. Its active ingredient is atinvicitinib, a synthetic selective JAK1 inhibitor.\"},{\"question\":\"For which dogs and condition is NUMELVI indicated?\",\"answer\":\"NUMELVI is indicated for controlling pruritus associated with allergic dermatitis in dogs 6 months of age and older.\"},{\"question\":\"How should NUMELVI be administered and at what dose?\",\"answer\":\"Administer NUMELVI orally once daily with food. The dose is 0.36 to 0.54 mg atinvicitinib per lb (0.8 to 1.2 mg atinvicitinib/kg) based on the provided dosing table.\"}]","NUMELVI - atinvicitinib tablets - Immunomodulator | PDF",1791857969]